How to bridge the gap between academia and industry
Shared interests, mutual gain, flexibility and trust are key to building win–win partnerships in drug development.
Connecting and engaging those who care about cancer
International oncology experts reunited as one oncology community to share the latest advances in the field at the ESMO annual meeting starting next week
A Virtual Train to ESMO travelling through 15 countries
With the “departure” of the virtual ESMO train in August, the ESMO Young Oncologists Committee (YOC) and the ESMO Climate Change Task Force are creating new opportunities for networking and sharing knowledge, while raising awareness on how climate change hits on cancer care
Cancer Control Principles
One step back to move forward in oncology workforce
The scope of the oncology care across resource-diverse settings has been long debated.
Cancer Research
Good night for good? Preventing sleeping cancer cells from awakening
Metastases are the main cause of cancer-related deaths. Preventing hibernating cancer cells from awakening therefore represents an urgent, unmet medical need.
Milestone in hereditary breast cancer: PARP inhibition benefits women with early-stage disease
Exciting new data show that adjuvant targeted agent olaparib after chemotherapy can cut the risk of BRCA-mutated breast cancer returning or spreading in women
Cancer Control Principles
Making assumptions about COVID-19 and cancer: a way to harm all
Since its very beginning, the COVID-19 pandemic has pushed people with health vulnerabilities to live in bubbles (symbolically). In parallel, we, as oncology professionals, have accepted more restrictive measures to control the pandemic and while attempting to protect those vulnerable groups, we ended up systematically excluding them from healthcare (literally).
Cancer Research
Conquering cancer: an attainable goal?
Following more than two decades of extraordinary developments and advancements in cancer research – from molecular mechanisms to clinical care to new enabling technologies, we are better equipped than ever before to deliver a much more personalised, targeted form of cancer treatment and care.
Hereditary cancers: diagnosed patients are only the tip of the iceberg
Although knowledge on pathogenic germline variants has improved over the years, researchers are hunting for new genetic causes of cancer to better identify families at higher risk to develop the disease
Despite success of targeted therapies, personalised medicine is not yet a reality in ovarian cancer
Expert says widely applicable predictive testing is needed to improve prevention, diagnosis and treatment